Ripples Brings Customizable Latte Art To Your Local Coffee Shop using edible nanoinks invented by Prof. Shlomo Magdassi of the Hebrew University of Jerusalem.
Jerusalem, Israel, June 18, 2015 – Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that it had signed multiple research and licensing agreements in the area of advanced materials with ICL (NYSE and TASE: ICL), a global manufacturer of products based on specialty minerals that fulfill essential needs of the world’s growing population in the agriculture, processed food and engineered materials markets.
The expanded collaboration includes a research agreement involving work in the field of materials and 3D printing of Prof. Shlomo Magdassi, the Casali Institute of Applied Chemistry, the Institute of Chemistry and the Center for Nanoscience and Nanotechnology at the Hebrew University, as well as a research and license agreement for an invention in the field of solar energy by Dr. Lioz Etgar from the Institute of Chemistry at the Hebrew University.
The innovative projects by Fourth Year students now face further development by the teams with the gudance of Yissum, the University's Technology Transfer Co.
NEW YORK, June 10, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) announced today that it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclosporine A. Cyclosporine A, when administered systemically (Sandimmune®, Neoral®), is an effective treatment for psoriasis, atopic dermatitis, pemphigus vulgaris and other severe inflammatory dermatoses.
Dr. Daniel Teper, the CEO of Immune Pharmaceuticals, commented: "Following our lead product candidate bertilimumab in bullous pemphigoid, we are excited to expand our immuno-dermatology portfolio with an innovative topical formulation of cyclosporine A. Additionally, we are further strengthening both our nanotechnology platform and our partnership with Yissum, which already includes NanomAbs®"
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that research underlying BL-9020, for the treatment of Type 1 diabetes, won the Hebrew University's prestigious Kaye Innovation Award.
The award was granted to Hebrew University immunologist Professor Ofer Mandelboim, who studied the function of a protein receptor called NKp46 in the development of Type 1 diabetes. Prof. Mandelboim showed that NKp46 present on Natural Killer cells has a critical role in the development of the disease in mice, and that inhibition of the receptor almost entirely prevented the development of diabetes. This groundbreaking research is the basis for BioLineRx’s BL-9020, a novel monoclonal antibody which targets the Natural Killer (NK) receptor NKp46 for the prevention and treatment of Type 1 diabetes.
Nanocrystalline cellulose has many interesting material properties, and can be used for example as a building material, in biocomposites, printed electronics and dye additives. The operation in the pilot plant is based on technology developed by an Israeli start-up company Melodea.
The camera and app also come with a set of rather cool features which we've not seen on any other camera of this type. The first is called RapidRecap, which lets you see a huge amount of activity on review in a short space of time. It does this by using some big computer crunching code on the cloud to cram together a day's worth of footage in a few seconds. It's very cool and something that more camera makers should try".
Chemical solution being advanced as fastest way of tackling environmental pollution.
Technology invenrted by Prof. Yoel Sasson of the Hebrew University of Jerusalem and will be displayed during Yissum's Energy & Cleantech conference on May 20th 2015.
Israel Prize laureate Dr. Haim (Howard) Cedar of the Hebrew University has conducted ground-breaking research that may add the Nobel Prize to his list of achievements.
Cedar, who specializes in DNA annotation -- the process of identifying the locations of genes, and coding regions in the genome -- joins VOI's Eve Harow in-studio to discuss his work. He says he is aiming at preventing, not merely curing, cancer.
A new technology developed by Prof. Amos Nussinovitch at the Robert H. Smith Faculty of Agriculture of the Hebrew University keeps peppers fresh for weeks!
Best Development in 3D Printing Equipment has been awarded to Nano Dimension. Nano Dimension is developing a 3D printing system, based on an invention of Prof. Shlomo Magdassi of the Hebrew university, for rapid prototyping of professional multi-layer PCBs (circuit boards). The company is developing technologies in 3 areas, nano-materials, the 3D printer itself and software dedicated to 3D printing. The printer is designed to print the conductive material, the insulating material and to do so layer by layer.
Prof. Alon Peled proposes a groundbreaking approach for enabling information sharing among public sector agencies, whose computer systems are notoriously complex.
New technology out of Hebrew University extends shelf-life of produce, though it may not yet be viable for the market.
There's nothing quite disappointing as discovering the head of lettuce you put in your fridge just a couple days ago is now brown and shriveled.
To counter the problem, Hebrew University’s Yissum technology transfer company has introduced a novel way to extend the shelf life of lettuce, cabbage, celery, spinach and parsley.
10 Israeli nanotech companies exhibited their cutting-edge solutions at Imaginenano 2015, Europe’s largest nanotechnology conference. 5 of them- are Yissum Staru Ups!
While medical cannabis is often used to ease pain or nausea, an Israeli-American biopharmaceutical company is developing medicines containing cannabinoids — chemical compounds from cannabis plants — to treat conditions including diabetes, inflammatory diseases (like arthritis, atherosclerosis and ulcerative colitis) and cardiovascular disorders.
ISA Scientific recently signed an exclusive worldwide licensing and collaboration agreement to establish therapies containing a specific cannabinoid called cannabidiol (CBD), with Yissum, the technology-transfer company of the Hebrew University of Jerusalem, Hadasit, the technology-transfer company of the Hadassah Medical Organization in Jerusalem, and the Kennedy Trust for Rheumatology Research (KIR) in the United Kingdom.
The licensed intellectual property is the result of many years of research and collaboration between renowned cannabinoid scientists, Raphael Mechoulam, Professor of medicinal chemistry, and Ruth Gallily, Professor of immunology, both from the Hebrew University; the distinguished immunologist, Professor Sir Marc Feldman, Director of the Kennedy Institute of Rheumatology; and prominent physicians and scientists at Hadassah Professors Chaim Lotan and Ronen Durst, and Dr. Lola Weiss.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents in order to facilitate the development of a topical nanoparticle formulation of Immune's neuropathic pain drug, AmiKet™.
The technology that Immune will be licensing was invented by Professor Simon Benita, from the Institute for Drug Research, the School of Pharmacy, and Faculty of Medicine at the Hebrew University, a renowned expert in development of drug delivery technology, and a primary inventor of NanomAbs, an antibody nanoparticle conjugate technology to deliver cancer drugs, already licensed by Immune from Yissum.
While the world is moving into a new era of Internet of Things (IoT), where all devices will be connected, there is a constant growing demand for cyber security innovations that will allow a balance between user privacy to the sharing of information. We believe that collaboration between the students and researchers of the Hebrew University and Kaspersky could yield innovations that would build tomorrow’s security demands” said Tamir Huberman, VP Business Development, Yissum
According to Yissum CEO Yaacov Michlin, 65 licensing and license option agreements were signed in 2014 with many different national companies, and a total of 596 agreements of various types were signed (including confidentiality agreements that precede deals, research services agreements, etc.). This is an increase in two parameters in comparison with 2013. Nine companies were founded on the basis of technology originating at the university, and raised $9 million.